Nature Medicine
10, 649 (2004)
doi:10.1038/nm0604-649c
CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, Dan G Duda, Lance L Munn, Ricky T Tong, Daniel C Chung, Dushyant V Sahani, Sanjeeva P Kalva, Sergey V Kozin, Mari Mino, Kenneth S Cohen, David T Scadden, Alan C Hartford, Alan J Fischman, Jeffrey W Clark, David P Ryan, Andrew X Zhu, Lawrence S Blaszkowsky, Helen X Chen, Paul C Shellito, Gregory Y Lauwers
& Rakesh K JainNat. Med.
10, 145−147 (2004).
The complete trial schema was omitted from the article. The protocol is outlined below.Table 1
|
